Filter Search for grants
Call key data
Advanced biomaterials for the Health Care
Horizon Europe - Cluster 4 - Destination 2: Increased autonomy in key strategic value chains for resilient industry
Estimated EU contribution per project
between € 6,000,000.00 and € 8,000,000.00
Link to the call
Link to the submission
This topic refers to the innovation market for Healthcare and Medicine, which affects many citizens and their needs. Several materials specifications and related innovations needs will support this topic such as renewable and recyclable materials, alternative active ingredients, design for circularity, lightweight materials. The topic should address several key policies of the European Union such as Circular Economy Action Plan, EU Chemicals strategy.
Proposals should address at least four of the following activities:
- To enable a fast development of new advanced novel injectable biomaterials, digital tools such as modelling, simulation and characterisation techniques (including those provided by analytical infrastructures) assisted by advanced methods e.g. physics-based methods, machine learning or artificial intelligence.
- The innovation market of medical applications is fast growing and dependent on advanced biocompatible materials that can be printed or injected. The 4D materials will change their 3D structures after external impact such as thermic, electric, mechanical or radiation treatment.
- Proposals shall demonstrate new engineering strategies that present functional characteristics beyond bio-compatibility, and express properties that can be used to control the physiological environment (shape-memory, self-healing properties) and induce a response.
- Proposals shall address biomaterials with antibacterial properties contributing to the widespread bottleneck of antimicrobial resistance often encountered in clinical care
- Demonstrate the scaling of injectable hydrogels, including those made of nanocomposite, natural and synthetic polymer-based biomaterials, bone cements, bio-ceramics and electronics.
- The design for circularity has to develop, when relevant, bio-degradable or bio-absorbable biomaterials that are gradually eliminated by the body after fulfilling a purpose.
The biomaterials used should be safe and sustainable by design (SSbD), taking also into account any specific medical requirements.
Proposals submitted under this topic should include a business case and exploitation strategy, as outlined in the introduction to this Destination.
This topic requires the effective contribution of SSH disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities. An early involvement of end users could be essential.
Projects should build on or seek collaboration with existing projects and develop synergies with other relevant European, national or regional initiatives, funding programmes and platforms.
Where relevant, proposals should seek links with and capitalise on the results of past and ongoing EU funded research projects, including the ones under Cluster 1 “Health” and Cluster 6 'Food, Bioeconomy, Natural Resources, Agriculture and Environment.
Projects are expected to contribute to the following outcomes:
- Develop the swiftly growing innovation market of medical applications, which is dependent on advanced biocompatible materials that can be printed or injected, including 4D materials that change their 3D structures following external impact (e.g. thermic, electric, mechanical or radiation treatment).
- Medical and/or surgical procedures will benefit from injectable materials for non-invasive surgical procedures.
- Some of their advantages include easy deliverability into the body, increased implantation precision, controllable release of therapeutic agents, antimicrobial properties and the possibility of monitoring or stimulating biological events.
Medical suppliers can commercialise injectable hydrogels, including those made of nanocomposite, natural and synthetic polymer-based biomaterials, bone cements, bio-ceramics and electronics.
Regions / countries for funding
Moldova (Moldova), Albania (Shqipëria), Armenia (Հայաստան), Azerbaijan (Azərbaycan), Belarus (Беларусь), Bosnia and Herzegovina (Bosna i Hercegovina / Босна и Херцеговина), Faeroes (Føroyar / Færøerne), Georgia (საქართველო), Island (Ísland), Israel (ישראל / إِسْرَائِيل), Kosovo (Kosova/Kosovë / Косово), Montenegro (Црна Гора), Morocco (المغرب), New Zealand (Aotearoa), North Macedonia (Северна Македонија), Norway (Norge), Serbia (Srbija/Сpбија), Tunisia (تونس /Tūnis), Türkiye, Ukraine (Україна), United Kingdom
Education and training institution, International organization, Non-Profit Organisation (NPO) / Non-Governmental Organisation (NGO), Other, Private institution, incl. private company (private for profit), Public Body (national, regional and local; incl. EGTCs), Research Institution incl. University, Small and medium-sized enterprise (SME)
To be eligible for funding, applicants must be established in one of the following countries:
- the Member States of the European Union, including their outermost regions
- the Overseas Countries and Territories (OCTs) linked to the Member States
- third countries associated to Horizon Europe - see list of particpating countries
Only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows:
- at least one independent legal entity established in a Member State; and
- at least two other independent legal entities, each established in different Member States or Associated Countries.
Any legal entity, regardless of its place of establishment, including legal entities from non-associated third countries or international organisations (including international European research organisations) is eligible to participate (whether it is eligible for funding or not), provided that the conditions laid down in the Horizon Europe Regulation have been met, along with any other conditions laid down in the specific call topic.
A ‘legal entity’ means any natural or legal person created and recognised as such under national law, EU law or international law, which has legal personality and which may, acting in its own name, exercise rights and be subject to obligations, or an entity without legal personality.
- Affiliated entities — Affiliated entities (i.e. entities with a legal or capital link to a beneficiary which participate in the action with similar rights and obligations to the beneficiaries, but which do not sign the grant agreement and therefore do not become beneficiaries themselves) are allowed, if they are eligible for participation and funding.
- Associated partners — Associated partners (i.e. entities which participate in the action without signing the grant agreement, and without the right to charge costs or claim contributions) are allowed, subject to any conditions regarding associated partners set out in the specific call conditions.
- Entities without legal personality — Entities which do not have legal personality under their national law may exceptionally participate, provided that their representatives have the capacity to undertake legal obligations on their behalf, and offer guarantees to protect the EU’s financial interests equivalent to those offered by legal persons.
- EU bodies — Legal entities created under EU law including decentralised agencies may be part of the consortium, unless provided for otherwise in their basic act.
- Joint Research Centre (‘JRC’)— Where provided for in the specific call conditions, applicants may include in their proposals the possible contribution of the JRC but the JRC will not participate in the preparation and submission of the proposal. Applicants will indicate the contribution that the JRC could bring to the project based on the scope of the topic text. After the evaluation process, the JRC and the consortium selected for funding may come to an agreement on the specific terms of the participation of the JRC. If an agreement is found, the JRC may accede to the grant agreement as beneficiary requesting zero funding or participate as an associated partner, and would accede to the consortium as a member.
- Associations and interest groupings — Entities composed of members (e.g. European research infrastructure consortia (ERICs)) may participate as ‘sole beneficiaries’ or ‘beneficiaries without legal personality’. However, if the action is in practice implemented by the individual members, those members should also participate (either as beneficiaries or as affiliated entities, otherwise their costs will NOT be eligible.
other eligibility criteria
Activities are expected to start at TRL 3-4 and achieve TRL 5-6 by the end of the project.
Relevance for EU Macro-Region
EUSAIR - EU Strategy for the Adriatic and Ionian Region, EUSALP - EU Strategy for the Alpine Space, EUSBSR - EU Strategy for the Baltic Sea Region, EUSDR - EU Strategy for the Danube Region
UN Sustainable Development Goals (UN-SDGs)
This topic is a two-stage proposal. The deadline for the first stage is 7 February 2024. If invited to submit at the second stage, the deadline is 24 September 2024.
This topic is part of the blind evaluation pilot under which first stage proposals will be evaluated blindly.
Applicants submitting a proposal under the blind evaluation pilot must not disclose their organisation names, acronyms, logos, nor names of personnel in Part B of their first stage application (see General Annex E).
Eligible costs will take the form of a lump sum.
The limit for a full application (Part B) is 50 pages.
In order to include a business case and exploitation strategy, the page limit in General Annex A of the General Annexes is exceptionally extended by 3 pages.